Abnormalities of cell structures in tumors: apoptosis in tumors.

EXS Pub Date : 2006-01-01 DOI:10.1007/3-7643-7378-4_9
Herman H Cheung, Vinay Arora, Robert G Korneluk
{"title":"Abnormalities of cell structures in tumors: apoptosis in tumors.","authors":"Herman H Cheung,&nbsp;Vinay Arora,&nbsp;Robert G Korneluk","doi":"10.1007/3-7643-7378-4_9","DOIUrl":null,"url":null,"abstract":"<p><p>A conceptual shift has occurred in recent years from considering cancer as simply a disease of deregulated cell proliferation to a view that incorporates the aberrant control of apoptosis into the equation. Apoptosis is an organized, genetically programmed cell death process by which multicellular organisms specifically destroy, dismantle and dispose of cells. In cancer cells, this tightly controlled process is suppressed by genetic lesions, allowing cancer cells to survive beyond their normal life span even in hostile environments that are prone to hypoxia and lack many trophic factor supports. In the last two decades, cancer researchers have made great strides in our understanding of the underlying molecular mechanism of apoptosis in chemoresistance generation and tumorigenesis. This tremendous increase in our knowledge of apoptosis in tumors has greatly impacted our perspective on carcinogenesis. Key regulators of apoptosis such as members of the Inhibitors of Apoptosis family and Bcl-2 family have been shown to play a pivotal role in allowing most cancer cells to escape apoptosis. The identification of specific targets involved in the suppression of apoptosis in cancer cells has facilitated the design and development of therapeutic strategies based on rational molecular approaches that aim to modulate apoptotic pathways. Many promising apoptosis-dependent strategies have been translated into clinical trials in the continued assessment of regimens that can effectively eradicate cancers.</p>","PeriodicalId":77125,"journal":{"name":"EXS","volume":" 96","pages":"201-21"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/3-7643-7378-4_9","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EXS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/3-7643-7378-4_9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

A conceptual shift has occurred in recent years from considering cancer as simply a disease of deregulated cell proliferation to a view that incorporates the aberrant control of apoptosis into the equation. Apoptosis is an organized, genetically programmed cell death process by which multicellular organisms specifically destroy, dismantle and dispose of cells. In cancer cells, this tightly controlled process is suppressed by genetic lesions, allowing cancer cells to survive beyond their normal life span even in hostile environments that are prone to hypoxia and lack many trophic factor supports. In the last two decades, cancer researchers have made great strides in our understanding of the underlying molecular mechanism of apoptosis in chemoresistance generation and tumorigenesis. This tremendous increase in our knowledge of apoptosis in tumors has greatly impacted our perspective on carcinogenesis. Key regulators of apoptosis such as members of the Inhibitors of Apoptosis family and Bcl-2 family have been shown to play a pivotal role in allowing most cancer cells to escape apoptosis. The identification of specific targets involved in the suppression of apoptosis in cancer cells has facilitated the design and development of therapeutic strategies based on rational molecular approaches that aim to modulate apoptotic pathways. Many promising apoptosis-dependent strategies have been translated into clinical trials in the continued assessment of regimens that can effectively eradicate cancers.

肿瘤细胞结构异常:肿瘤细胞凋亡。
近年来,观念发生了转变,从单纯地认为癌症是一种细胞增殖失控的疾病,到将细胞凋亡的异常控制纳入其中。细胞凋亡是一种有组织的、遗传编程的细胞死亡过程,多细胞生物通过这种过程特异性地破坏、分解和处置细胞。在癌细胞中,这种严格控制的过程被遗传病变抑制,使癌细胞即使在容易缺氧和缺乏许多营养因子支持的恶劣环境中也能存活超过正常寿命。在过去的二十年里,癌症研究人员在我们对细胞凋亡在化疗耐药产生和肿瘤发生中的潜在分子机制的理解方面取得了很大的进展。我们对肿瘤细胞凋亡知识的巨大增长极大地影响了我们对癌变的看法。凋亡的关键调节因子,如凋亡抑制剂家族成员和Bcl-2家族成员,已被证明在允许大多数癌细胞逃避凋亡中发挥关键作用。在肿瘤细胞中抑制凋亡的特定靶点的识别促进了基于合理分子方法的治疗策略的设计和发展,旨在调节凋亡途径。许多有希望的细胞凋亡依赖策略已经转化为临床试验,以持续评估能够有效根除癌症的方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
EXS
EXS
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信